摘要
缺氧是由于肿瘤细胞生长速度快、血液供应不足而在肿瘤环境中经常出现的一种情况。越来越多的证据表明,缺氧在癌症休眠和癌症代谢中发挥重要作用,增加干活动并引起癌症的发生和发展。 这种情况可能影响缺氧诱导因子(HIF)的产生,螺旋转录因子通过调节参与血管生成,糖酵解代谢和其他生物机制的基因参与癌发生和肿瘤生长。在常氧条件下,使用氧作为底物,HIF被脯氨酰羟化酶(EGLN 1-3,也称为PHD 1-3)灭活。一旦水解,它就会结合一种名为Von Hippel Lindau蛋白(VHL)的蛋白质进行降解,而在缺氧条件下会发生稳定化和核转位,从而导致癌基因活化。它有三种异构体HIF-1 HIF-2和HIF-3。研究最多的因子是HIF-1,它是由两种形式组成的异二聚体,形式α以氧依赖的方式表达,β形式是组成型表达的。 其在肿瘤微环境中的存在可以促进VEGF,HGF,Met质子基因的表达,其诱导细胞外基质和TWIST基因的降解,其反过来涉及称为上皮 - 间充质转换(EMT)的癌细胞转移机制。在这篇综述中,我们总结了不同类型癌症中HIF作用的最重要发现,重点是其诱导肿瘤细胞生长的特性,并突出其在不同癌症部位的不良预后价值。
关键词: HIF-1,转移,肿瘤进展,缺氧,微环境,代谢途径。
Current Molecular Medicine
Title:Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Volume: 18 Issue: 6
关键词: HIF-1,转移,肿瘤进展,缺氧,微环境,代谢途径。
摘要: Hypoxia is a condition always present in tumor environment owing to the fast growth of tumor cells not supported by adequate blood supply.
There is increasing evidence that hypoxia plays an important role in cancer dormancy and cancer metabolism, increasing stemness activity and bringing about cancer initiation and progression.
This condition may influence the production of hypoxia inducible factor (HIF) a helix transcription factor which is involved in carcinogenesis and tumor growth through the regulation of genes involved in angiogenesis, glycolytic metabolism and other biological mechanisms.
In normoxia condition HIF is inactivated by prolyl hydroxylase enzymes (EGLN 1–3, also known as PHD 1–3) using oxygen as a substrate. Once hydroxilated it binds to a protein called Von Hippel Lindau protein (VHL) for its degradation, whereas in hypoxia condition stabilization and nuclear translocation occur, leading to oncogenes activation. It has got three isoforms HIF-1 HIF-2 and HIF-3. The most studied factor is HIF-1 which is a heterodimer consisting of two forms, the form α is expressed in manner oxygen dependent, the form β is expressed constitutively.
Its presence in tumor microenvironment could foster among other the expression of VEGF, HGF, Met protoncogene which induces degradation of the extracellular matrix and TWIST gene, which is in turn involved in a mechanism of cancer cell metastasis called epithelial-mesenchimal transition(EMT). In this review, we summarize the most important findings in HIF action in different types of cancer focusing on its properties to induce tumor cell growth and highlighting its poor prognostic value in different cancers sites.
Export Options
About this article
Cite this article as:
Role of HIF-1 in Cancer Progression: Novel Insights. A Review, Current Molecular Medicine 2018; 18 (6) . https://dx.doi.org/10.2174/1566524018666181109121849
DOI https://dx.doi.org/10.2174/1566524018666181109121849 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
Current Medicinal Chemistry The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Current Medicinal Chemistry Trace of Long Non-Coding RNAs in Signaling Pathways in Thyroid Cancer
Current Signal Transduction Therapy Lipid Nanoformulations for Oral Delivery of Bioactives: An Overview
Current Drug Therapy Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Electro-Organic Synthesis of New Esculetin Derivatives Based on 1,6-Conjugate Addition
Current Organic Chemistry Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Towards the Chemoinformatic-Based Identification of DNA Methyltransferase Inhibitors: 2D- and 3D-Similarity Profile of Screening Libraries
Current Computer-Aided Drug Design Induction of HT-29 Colon Cancer Cells Apoptosis by Pyrogallol with Growth Inhibiting Efficacy Against Drug-Resistant Helicobacter pylori
Anti-Cancer Agents in Medicinal Chemistry Squalamine: A Polyvalent Drug of the Future?
Current Cancer Drug Targets The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets What Makes Species Productive of Anti-Cancer Drugs? Clues from Drugs’ Species Origin, Druglikeness, Target and Pathway
Anti-Cancer Agents in Medicinal Chemistry Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Minimally Invasive Transoral Surgical Treatment for Oropharyngeal Carcinoma
Current Cancer Therapy Reviews Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry